This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Clinical and Immunogenicity Data of Pneumococcal Vaccines in Lung Diseases
Evidence indicates that pneumococcal vaccinations in patients with COPD can help prevent CAP and acute exacerbations. Administration of pneumococcal vaccines early in the course of COPD can help in the maintenance of stable health status. However, both vaccination awareness and coverage are poor among these groups of patients.1
One of the important causes of exacerbations in COPD is S. pneumoniae. A prospective observational study evaluated the impact of PCV13 on the development of exacerbations in patients with COPD. As compared with the non-vaccinated group, the rate of hospitalisation was lower in the vaccinated group (32% vs. 18%). In the non-vaccinated group, the adjusted OR for risk of hospitalisation was 2.77 (P = 0.044). Therefore, the study revealed that in absence of PCV13, the risk of hospitalisation in patients with COPD is almost tripled.2
In the 2017 Cochrane systematic review, 12 randomised controlled trials were reviewed to determine the efficacy of injectable pneumococcal vaccines in patients with COPD. The study involved 2171 patients with COPD, the average age of participants being 66 years. The study revealed that vaccination with PCV13 and PPSV23 significantly lowered the likelihood of COPD exacerbation (OR, 0.60, 95% CI, 0.39-0.93). Some evidence indicated the benefits of pneumococcal vaccination in patients with COPD.3
A review of pneumococcal vaccine efficacy studies reported that the pneumococcal vaccine efficacy in individuals with underlying risk factors, such as COPD or chronic respiratory diseases, varied between −338% and 43%. The overall efficacy observed was 29% (95% CI, −39%-63%) in adults with chronic respiratory diseases, aged ≥50 years.4
A study analysed the effectiveness of PCV13 and PPSV23, and long-term formation of adaptive immunity in adult patients with COPD. The clinical effects of vaccination were assessed 1 and 4 years after immunisation. After 4 years, the study group vaccinated with PCV13/PPSV23 demonstrated a 50% decline in the number of patients with COPD exacerbations (P<0.001). At 1 year after vaccination, the vaccinated patients with COPD had elevated levels of IgG antibodies against PCV13 and PPSV23, as compared with the baseline. The study interpreted that initial immunisation with PCV13, followed by a booster dose of PPSV23, should be included in the basic therapy for patients with COPD.5
CAP, community-acquired pneumonia; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.